{"analyses":[{"ciLowerLimit":"0.05","ciPctValue":"95","ciUpperLimit":"1.44","groupIds":["OG000","OG002"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","paramType":"Odds Ratio (OR)","paramValue":"0.26","testedNonInferiority":false},{"ciLowerLimit":"0.08","ciPctValue":"95","ciUpperLimit":"1.76","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","paramType":"Odds Ratio (OR)","paramValue":"0.36","testedNonInferiority":false}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"35"},{"groupId":"OG001","value":"35"},{"groupId":"OG002","value":"38"}],"units":"Participants"}],"description":"Skeletal Related Event (SRE), defined as \\>1 of the following: pathological bone fracture, spinal cord compression, surgery or radiation therapy to bone (including the use of radioisotopes).","groups":[{"description":"Open-label intravenous (IV) bisphosphonate once every 4 weeks (Q4W)","id":"OG000","title":"Bisphosphonate IV Q4W"},{"description":"Open-label denosumab 180 mg by subcutaneous injection once every 12 weeks (Q12W)","id":"OG001","title":"Denosumab 180 mg Q12W"},{"description":"Open-label denosumab 180 mg by subcutaneous injection once every 4 weeks (Q4W)","id":"OG002","title":"Denosumab 180 mg Q4W"}],"paramType":"NUMBER","populationDescription":"All participants exposed to investigational product during the treatment phase.","reportingStatus":"POSTED","timeFrame":"Day 1, week 25","title":"Skeletal Related Events","type":"SECONDARY","unitOfMeasure":"Participants"}